Pseudomonas aeruginosa – Pathogenesis and Pathogenic Mechanisms

Alaa Alhazmi¹,²

¹ Department of Biology, Lakehead University, Thunder Bay, Ontario, Canada
² Department of Medical Laboratory Technology, Jazan University, Jazan, Kingdom of Saudi Arabia

Correspondence: Alaa Alhazmi, Department of Biology, Lakehead University, 955 Oliver Road, Thunder Bay, ON, P7B 5E1, Canada. Tel: 1-807-766 7428. Email: aalhazmi@lakeheadu.ca

Received: December 9, 2014   Accepted: January 3, 2015   Online Published: February 3, 2015
doi:10.5539/ijb.v7n2p44   URL: http://dx.doi.org/10.5539/ijb.v7n2p44

Abstract

Pseudomonas aeruginosa is a common bacterium, Gram-negative opportunistic pathogen capable of infecting humans with compromised natural defenses and causing severe pulmonary disease. It is one of the leading pathogen associated with nosocomial infections. It has a vast arsenal of pathogenicity factors that are used to interfere with host defenses. Pathogenesis in P. aeruginosa facilitates adhesion, modulate or disrupt host cell pathways, and target the extracellular matrix. The propensity of P. aeruginosa to form biofilms further protects it from antibiotics and the host immune system. P. aeruginosa is intrinsically resistant to a large number of antibiotics and can be acquired resistance to many others, making treatment difficult. P. aeruginosa provokes a potent inflammatory response during the infectious process. The majority of mortalities in immunocompromised patients; cystic fibrosis, can be attributed to the progressive decline of lung function resulting from chronic infection by pathogens such as P. aeruginosa. Antibiotic treatment of chronic P. aeruginosa infections may temporarily suppress symptoms; however, they do not eradicate the pathogen. Lung diseases caused by P. aeruginosa are a leading cause of death in immunocompromised individuals as well as in children. Although immunocytes recruitment is critical to augment the host defense, excessive neutrophil accumulation results in life-threatening diseases, such as acute lung injury, as well as acute respiratory distress syndrome. Several virulence factors have been studied for their roles as potential vaccine candidate, although there is currently no clinically accepted vaccine. Understanding host-pathogen interaction is critical for the development of effective therapeutic strategies to control the damage in the lung.

Keywords: Pseudomonas aeruginosa, nosocomial infection, virulence factors, antibiotic resistance, cystic fibrosis

P. aeruginosa is a motile, non-fermenting, Gram-negative organism belonging to the family Pseudomonadaceae. In 1850s, Sédillot observed that a blue-green discharge was frequently present and associated with infection in surgical wound dressings (Lyczak, Cannon, & Pier, 2000). The infectious organism has a rod-shaped and blue-green pigmented bacterium (Lartigau, 1898). By 1961, the ability of this organism to cause both severe acute and chronic infections was recognized (Freeman, 1916). In 1960s, P. aeruginosa emerged as an important human pathogen (Doggett, 1979). Despite anti-pseudomonas activity being one of the pharmaceutical drug discoveries for several decades. It remains one of the most recalcitrant and difficult to treat organisms. Accordingly, P. aeruginosa result has achieved Superbug status.

At 6.3 million base pair (Mbp), P. aeruginosa genome is markedly as a large genome (encoding 5567 genes) compared to 4.64 Mbp (4279 genes) in Escherichia coli K12, 2.81 Mbp (2594 genes) in Staphylococcus aureus N315, and 1.83 Mbp (1714 genes) in Haemophilus influenza Rd. Also, the proportion of predicted regulatory genes in P. aeruginosa genome is greater than in all other sequenced bacterial genomes (Stover et al., 2000; Lambert, 2002), thus lending to its adaptability to varying environments. P. aeruginosa has a broad range of growth substrate, minimal nutrient requirements; non-fastidious microorganisms (Favero, Carson, Bond, & Petersen, 1971). The organism is tolerant of temperatures as high as 50ºC and is capable of growing under aerobic conditions, as well as anaerobic conditions (van Hartingsveld & Stouthamer, 1973). Despite possessing a large number of virulence factors. In spite of this, P. aeruginosa is truly a challenging pathogen in the hospital setting as it is resistant to many antibiotics. Also, it is capable of forming hardy biofilms, both within the body and on the surfaces of medical instruments (Consterton, Stewart, & Greenberg, 1999; Hancock, 1998, Moreau-Marquis, Stanton, & O’Toole, 2008). P. aeruginosa continues to be problematic from a treatment perspective.
**P. aeruginosa** is armed with potent virulence factors. Although ubiquitously present in the environment, *P. aeruginosa* never causes disease in an immunocompetent host as the immune system effectively prevents the infection. However, the pathogen causes severe infections in Cystic Fibrosis (CF) patients. In CF, a genetic defect in lung innate immunity underlies the development of persistent infection with *P. aeruginosa* that gradually leads to irreversible tissue damage. Several conserved microbial structures in *P. aeruginosa* are recognized by Toll-like receptors (TLRs) and NOD-like receptors (NLRs); which have been implicated in activating the host innate immune responses to *P. aeruginosa* (DiMango, Zar, Bryan, & Prince, 1995; Skerrett, Wilson, Liggitt, & Hajjar, 2007).

There are a number of clinical diseases associated with *P. aeruginosa* infection. However, *P. aeruginosa* is an opportunistic organism infecting; burn, CF, leukemic, transplant, neutropenic, long-term urinary catheters, and diabetic patients as well intravenous drug abusers.

### 1. Nosocomial Infection Due to *P. aeruginosa*

Nosocomial (hospital-acquired) infections are those not present or incubating at the time of hospital admission, but usually develop post-admission. The 2006-7 report by National Healthcare Safety Network (NHSN) at the Centers for Disease Control and Prevention (CDC) ranked *P. aeruginosa* as the sixth most common healthcare associated pathogen-causing infection. Also, it is typically found at even higher rank in studies focused on the intensive care unit (ICU). The NHSN reports that in United States in 2006-7, 8% of all hospital-associated infections were due to *P. aeruginosa*, with *P. aeruginosa* causing 3% of central line-associated bloodstream infections, 6% of surgical site infections, 10% of catheter-associated urinary tract infection and 16% of ventilator-associated pneumonia (VAP) infections (Hidron et al., 2008). Mechanical ventilation, antibiotic therapy, surgery, and chemotherapy are the major predisposing factors contributing to the acquisition of a *P. aeruginosa* infection in the hospital (Thuong et al., 2003). It is worth noting however that difficulties in treatment of such infections and the associated morbidity and mortality, have made *P. aeruginosa* on of the most feared hospital pathogens.

#### 1.1 Burn Wound Infections

*P. aeruginosa* is the leading cause of invasive infections in burn patients; 75% of all deaths in patients with severe burn are related to sepsis from invasive burn wound infection (Baker, Miller, & Trunkey, 1979; Bang, Sharma, Sanyal, & Najjadah 2002; Barrow, Spies, Barrow, & Herndon, 2004). In addition to wounded skin injury, inhalation injury is common in burn patients. This results in edema and sloughing of the respiratory tract mucosa and impairment of the normal mucociliary clearance mechanism, thus making these patients more susceptible to upper respiratory tract infections as well as *P. aeruginosa* pneumonia (Church, Elsayed, Reid, Winston, & Lindsay, 2006).

Although Gram-positive organisms such as *Staphylococcus aureus* and *Streptococcus pyogenes* are typically the first microorganisms to colonize the site of infection, after that other microbes including *P. aeruginosa* being to colonize these wounds (Altoparlak, Erol, Akcay, Celebi, & Kadanali, 2004; MacMillan, 1980). Success with early wound excision practices was shown to contribute to the prevention of invasive infections disseminating from the wound site (Barret & Herndon, 2003). Animal studies of partial-thickness cutaneous burns showed that mature biofilms could develop in 48 to 72 hours, indicating a major potential source of further difficulties in antimicrobial therapy at these sites (Trafny, 1998).

In addition to the *P. aeruginosa* virulence factors that undoubtedly contribute to the success of *P. aeruginosa* as a pathogen in the burn patients, described later, the impairment of host immunity, beyond simple loss of the skin’s physical barrier, plays a role in enhancing susceptibility to infection. Recent studies have demonstrated that thermal injury causes impaired production of the host defense peptides β-defensins in the tissues surrounding the wound. These immunomodulatory peptides have been proposed to play an important role in primary defense against *P. aeruginosa* and synthetic β-defensin was recently shown to be protective against *P. aeruginosa* infection in a burned mouse model (Kobayashi et al., 2008).

#### 1.2 Bacteremia

*P. aeruginosa* is among the five leading causes of nosocomial bacteremia and frequently leads to sepsis. In the 1960s and early 1970s, aminoglycosides and polymyxins were the only options for treatment of *P. aeruginosa* bacteremia but were found to be fairly ineffective for these infections. Mortality of greater than 50% was reported when mortality was used as the end point (Fishman & Armstrong, 1972; Whitecar, Luna, & Bodey, 1970), and was as high as 70% in febrile neutropenic patients (Bodey, Jadeja, & Elting, 1985). Despite the introduction of effective anti-pseudomonal β-lactams and the associated reduction in mortality rates, *P. aeruginosa* bacteremia is still one of
the most feared nosocomial infections. These infections are generally associated with higher mortality than with other infecting pathogens, and persistence, particularly related to device-related bacteremia, continues to plague patients (Rello, Ricart, Mirelis, Quintana, Gurgui, Net, & Prats, 1994).

The main distinguishing feature of *P. aeruginosa* sepsis is the presence of ecthyma gangrenous, and these infarcted skin lesions occur only in markedly neutropenic patients (Pier & Ramphal, 2005). When *P. aeruginosa* disseminates from a site of local infection, it gains access to the bloodstream by breaking down epithelial and endothelial tissue barriers (Kurahashi et al., 1999). To evade the bactericidal activity of the serum complement, *P. aeruginosa* produces a smooth lipopolysaccharide (LPS) (Hancock et al., 1983; Pier & Ames, 1984); full-length O side-chain of the bacteria.

1.3 Hospital-Associated Pneumonia

The human respiratory tract presents a favorable environment to which *P. aeruginosa* has become particularly well adapted. *P. aeruginosa* has the formidable ability to cause both chronic infections in the lung of CF patients and acute nosocomial pneumonia (Blondel-Hill and Fryters, 2006). Animal model studies of *P. aeruginosa* pneumonia have demonstrated the involvement in virulence of proteases, flagella, pili and LPS O side chains as well as the delivery of the extracellular toxins ExoS, ExoT and ExoU via a type III secretion system (T3SS). For example, administration of anti-perV antibodies blocking the T3SS has been shown to offer protection against acute *P. aeruginosa* pneumonia when tested in animal studies (Faure et al., 2003; Shime et al., 2001).

1.4 Ventilator-Associated Pneumonia

*P. aeruginosa* is commonly found to be the first or second major pathogen causing VAP (Hidron et al., 2008). It is the most common multidrug resistance pathogen involved in this disease and recovery rate of *P. aeruginosa* is increased with increased duration of mechanical ventilation. In addition to being amongst the most common pathogens causing VAP, *P. aeruginosa* is also amongst the most lethal pathogens, since reports suggest up to 70-80% mortality when the organism remains confined to the lung (Chastre & Fagon, 2002), with directly attributable mortality rates reaching 38% (Fagon et al., 1993).

2. *P. aeruginosa* Infections in Cystic Fibrosis

Cystic fibrosis (CF) is; an autosomal receive genetic disorder, the most common fatal genetic disease. CF is caused by a mutation in a gene on chromosome 7 known as CFTR (cystic fibrosis transmembrane conductance regulator). Most common mutant allele is ΔF508 (or F508del) mutation, which is a three-nucleotide deletion of a phenylalanine residue and subsequent defective intracellular processing of the CFTR protein that is an important chloride channel (Bobadilla, Fine, & Farrell, 2002). CF is affecting 1:2,500 in the Caucasian population (Ratjen & Döring, 2003). CF is multi-system disease, which affects mainly lung and digestive system. Most CF-related deaths are due to lung disease (Bobadilla, Fine, & Farrell, 2002).

Mortality in this afflicted population is mainly attributed to chronic respiratory infections and the associated gradual deterioration of lung function. There are several pathogens known to play a role in CF lung infection, with *Staphylococcus aureus* and *Haemophilus influenzae* being the predominant pathogens colonizing in infancy and early childhood, and eventual replacement by *P. aeruginosa*. However, *P. aeruginosa* is often isolated from patients less than 2 years of age and is the most predominant concern in adults (Gibson, Burns, & Ramsey, 2003; Hudson, Wielinski, & Regelmann, 1993). Up to 90% of individuals suffering from CF become infected with *P. aeruginosa* during their lifetime, and this organism is the leading cause of morbidity and mortality among those patients. It is dominant pathogen in chronic lung infection in CF. In the majority of cases, colonization of the CF airway by *P. aeruginosa* leads to a chronic infection that is resistant to antimicrobial therapy (MacEachran et al., 2007; Döring et al., 2014). Chronic colonization and infection with *P. aeruginosa* is an inevitable reality for the majority of adults with CF, as over 80% of adults over the age of 18 years return positive cultures for *P. aeruginosa* (Hodson, 2000). The nature of this disease is critical in understanding why *P. aeruginosa* dominates as the primary pathogen in CF patients and so host pathology is addressed below.

The defective gene involved in CF encodes for CFTR resulting in pathological changes in organs that express CFTR, including lungs. In a normal airway epithelial cell, the gene encoding for CFTR, regulates the transport of chloride, sodium, and water. Abnormalities of the CFTR gene product lead to a thick and dehydrated mucous secretion that impairs mucociliary clearance of bacterial pathogens (Collins, 1992). In the normal lung, the mucus layers function in binding and clearance of inhaled pathogen, and although the bacterial load can be quite high in the upper airways, the lower airways remain free of bacteria (Bals, Weiner, & Wilson, 1999). Due to the characteristic thickened mucus associated with CF lung disease, and resulting an inability of ciliary beating to remove the mucus, invading pathogens become trapped in the mucus layer. As a result, a constant presence of
bacteria with expression pathogen-associated molecular patterns (PAMPs) leads to chronic inflammation, consequently damaging the epithelial surface (Donaldson et al., 2006; Greene et al., 2005; Kolberg, Mossberg, Afzelius, Philipson, & Camner, 1978).

A novel concept of host susceptibility emerged that the epithelial cells use CFTR as a receptor for internalization of *P. aeruginosa* and subsequent removal of bacteria from the airway surface (Pier, Grout, & Zaidi, 1997; Pier et al., 1996). Accordingly, CFTR is considered as a pattern recognition molecule that extracts *P. aeruginosa* LPS from the organism’s surface into epithelial cells (Schroeder et al., 2002). The prevention of CFTR-*P. aeruginosa* interactions led to decreased bacterial clearance and increased bacterial burdens in the lungs.

### 2.1 Adaptation Occurring During Chronic Infection

CF patients frequently become colonized in the upper airways by unrelated environmental isolates of *P. aeruginosa* (Salunkhe et al., 2005; Speert et al., 2002). During the process of infection, a number of adaptations occur leading to the characteristic persistence and antibiotic resistance of isolates found from chronic infection. Amongst the most common adaptations of *P. aeruginosa* found in CF isolates, is the conversion to mucoid phenotype due to overexpression of alginate (Govan & Deretic, 1996). Environmental isolates usually present a non-mucoid phenotype, as *P. aeruginosa* penetrates the thickened mucus lining of the airways, travelling down the oxygen gradient, increased expression of alginate and a switch to a mucoid phenotype occur (Grimwood, 1992; Starner & McCray, 2005). This phenotype often occurs coincidently with the establishment of chronic infection and becomes stabilized by regulatory mutations as described earlier. The mucoid form of *P. aeruginosa* is associated with 90% of *P. aeruginosa* CF infections compared to only 2% of *P. aeruginosa* non-CF infections (Dodge, 1969; Dodge, Harrison, & Carter, 1971). This phenotype is often coordinately regulated with a loss of flagella by the alternative sigma factor AlgT (Tart, Wolfgang, & Wozniak, 2005). The loss of flagella causes not only loss of motility, but also decreased activation of host inflammatory mediators (Cobb, Mychaleckyj, Wozniak, & Lopez-Boado, 2004).

Other easily identified morphological adaptations of *P. aeruginosa* include the switch from smooth to rough colony morphology and the appearance of small colony variants. The rough colony morphology is representative of strains that have lost the LPS O-antigen (Hancock et al., 1983). As the O-antigen is the immunodominant portion of the LPS, this adaptation leads to a less virulent phenotype. It also makes rough isolates more susceptible to complement killing and perhaps explains in part why these organisms virtually never cause invasive infections. Modifications to the lipid A moiety of the LPS are also observed. These include the addition of palmitate, aminoarabinose and the retention of 3-hydroxydecanoate (Ernst et al., 2007). The small colony phenotype is less well understood but is of considerable interest as these isolates exhibit increased antibiotic resistance. Isolates exhibiting this phenotype have been found to be hyperpiliated with increased abilities in twitching and biofilm formation, and with decreased ability for swimming (Hauessler et al., 2003).

Another phenotype of relevance to antimicrobial therapy and resistance is the hypermutator phenotype, which is frequently observed in CF isolates, but less commonly in nosocomial isolates of *P. aeruginosa* (Oliver, Canton, Campo, Baquero, & Blazquez, 2000). This phenotype, characterized by an up to 1000-fold increased mutation frequency, has been attributed to mutations in genes encoding DNA replication and repair mechanisms, such as mutS, mutL, and mutY. Most importantly, these hypermutator isolates can develop mutational resistance more readily during a course of antimicrobial therapy than do non-mutator isolates. The hypermutator phenotype can give rise to a variety of mixed morphologies within the lung, including those described above (Hogardt et al., 2007). These diverse populations can colonize or infect different compartments within the lung and often have variable antimicrobial susceptibilities with virulence properties (Foweraker, Laughton, Brown, & Bilton, 2005; Irvin, Govan, Fyfe, & Costerton, 1981; MacLeod et al., 2000; Pai & Nahata, 2001).

Comparison of *P. aeruginosa* isolates from the CF lung to strains from non-CF patients showed clearly that CF isolates tend to demonstrate an overproduction of β-lactamase, loss of OprD and an overproduction of MexXY. This efflux pump overproduction leads to high-level aminoglycoside resistance and the overproduction of this and other efflux systems also lead to quinolone resistance, amongst which MexCD-OprJ was the most frequent (Henrichfreise, Wiegand, Pfister, & Wiedemann, 2007).

### 2.2 Antimicrobial Therapy for Treatment of *P. aeruginosa*

*P. aeruginosa* isolates from CF patients frequently develop multi-drug resistance. Combination therapy can be used to avoid resistance development and to exploit the synergistic effects of the bactericidal antibiotics. The use of aerosols allows for drugs to be delivered directly to the lung in CF patients and a number of antibiotics including gentamicin, tobramycin, colistin, ceftazidime, carbencillin aztreonam and amikacin have been
administered as aerosols to CF patients, although approved formulation and adequate controlled studies have not been performed on most of these (Hodson, Penketh, & Batten, 1981; Stead, Hodson, & Batten, 1987).

2.2.1 Antimicrobial Therapy for Colonization and Initial Infection

Eradication of \textit{P. aeruginosa} from the CF lung is possible only in the early stages of colonization. At this point, the bacterial load tends to be low, and the organism is non-mucoid and has not begun to undergo significant morphological changes. Aggressive antimicrobial treatment upon first isolation of \textit{P. aeruginosa} has been demonstrated in most cases to delay and occasionally prevent the onset of chronic infections resulting in a better quality of life and a greater life expectancy (Nixon et al., 2001; Rosenfeld, Ramsey, & Gibson, 2003). Successful eradicating is judged by the observation of at least three consecutive negative cultures at intervals of at least month. After one year of negative cultures following the onset of antimicrobial therapy, any isolation of \textit{P. aeruginosa} is considered to represent a new isolate (Gibson, Burns, & Ramsey, 2003). Aggressive antimicrobial use at the early stage has proven in certain cases to be successful, with a number of patients having remained culture negative for \textit{P. aeruginosa} for several years after treatment (Frederiksen & Hoiby, 1997; Ratjen, Doring, & Nikolaizik, 2001).

2.2.2 Antimicrobial Therapy for Chronic Infections

Once chronic infection has been established by \textit{P. aeruginosa}, the high bacterial load present in the lung, as well as the phenotypic changes occurring in the pathogen complicates antimicrobial therapy. The high bacterial load and thickened mucus are barriers to the attainment of sufficient exposure of the entire bacterial population to bactericidal concentrations of antibiotics (Mendelman et al., 1985). Administration of insufficient concentrations of antibiotics adds increased selective pressure for resistant phenotypes, thereby enhancing the diversity of the population, lending further difficulties to effective treatment (MacLeod et al., 2000; Pai & Nahata, 2001).

Antimicrobial therapy is used during chronic infections in CF for two main purposes: maintenance therapy and treatment of acute exacerbations of infection (Doring et al., 2000). Maintenance therapy is recommended for CF patients with chronic \textit{P. aeruginosa} infections in order to reduce bacterial load and maintain overall lung function. Unfortunately, a number of side effects are associated with long-term antimicrobial use including loss of hearing, increased cough, alterations of the voice, and the appearance of antibiotic resistant strains. The use of on/off cycles of intermittent drug administration led to the reduced occurrence of these side effects (Ramsey et al., 1999).

3. Pathogenesis and Major Virulence Factors

Pathogenesis in \textit{P. aeruginosa} is mediated by multiple bacterial virulence factors that facilitate adhesion and/or disrupt host cell signaling pathways while targeting the extracellular matrix (Figure 1). \textit{P. aeruginosa} stands out as a unique and threatening organism as it is capable of causing severe invasive disease and of evading immune defenses causing persisting infections that are nearly impossible to eradicate (Pier & Ramphal, 2005). The subsequent tissue damage, invasion, and dissemination of \textit{P. aeruginosa} are likely attributed to the many virulence factors it produces. These virulence factors play an initial role in motility and adhesion to the epithelium. These virulence factors are thought to be critical for maximum virulence of \textit{P. aeruginosa}; however, based on observations of diverse plant and animal models, the relative contribution of any given factor may vary with the type of infection (Preston et al., 1995; Rahme et al., 1997; Tamura, Suzuki, & Sawada, 1992; Tamura, Suzuki, Kijima, Takahashi, & Nakamura, 1992; Tang et al., 1996). Several of these virulence factors have also been studied for their roles as potential vaccine candidate although there is currently no general accepted vaccine. The following section briefly outlines several prominent putative virulence factors produce by \textit{P. aeruginosa} and their proposed roles in contributing to disease.

3.1 Lipopolysaccharide

The LPS is a predominant component of the outer membrane of \textit{P. aeruginosa}. Bacterial LPS typically consist of a hydrophobic domain known as lipid A (or endotoxin), a non-repeating core oligosaccharide, and a distal polysaccharide (or O-antigen) (Raetz & Whittfield, 2002). The composition of O-antigen determines the serotypes of the \textit{P. aeruginosa} isolate and currently there are 20 serotypes based on serological reactivity of the O-antigen (Liu & Wang, 1990). LPS plays a prominent role in activation the host’s innate (TLR4, NLRP1, NLRP2, and NLRP3) and adaptive (or acquired) immune responses; and, eventually causes dysregulated inflammation responses that contribute to morbidity and mortality (Heine, Rietschel, & Ulmer, 2001).

Recognition of LPS occurs largely by TLR4–MD2–CD14 complex, which is present on many cell types including macrophages and dendritic cells. Recognition of lipid A also requires an accessory protein, LPS-binding protein (LBP), which converts oligomeric micelles of LPS to a monomer for delivery to CD14,
which is high-affinity membrane protein that can also circulate in a soluble form (Poltorak et al., 1998; Wright, Ramos, Tobias, Ulevitch, & Mathison, 1990; Shimazu et al., 1999; Qureshi et al., 1999; Hoshino et al., 1999). In addition, NLRs regulate both inflammation and pyroptosis. The activation of NLRs results in an assembly of complex structures called inflammasomes (Franchi, Muñoz-Planillo, & Núñez, 2012). The NLRP1 inflammasome was first described in 2002 in human monocytes as a molecular compound that responds to LPS (Martinon, Burns, & Tschopp, 2002). Many stimuli that trigger assembly of the inflammasomes have been described. LPS also reported to activate NLRP3 when administered in the presence of ATP (Stutz, Golenbock, & Latz, 2009), as well as NLRP2 (Lamkanfi, & Dixit, 2009). A number of LPS vaccines have been investigated for use in CF patients in phase II and III clinical trials; however, these have not been successful (Doring & Pier, 2008; Hanessian, Regan, Watson, & Haskell, 1971; Langford & Hiller, 1984; Pennington, 1979; Pennington & Miler, 1979). The LPS based vaccines provided little immunity and did not appear to protect the patients from infection with *P. aeruginosa* (Pier, 2003).

Figure 1. *P. aeruginosa* Pathogenesis and Major Virulence Factors

Pathogenesis in *P. aeruginosa* is mediated by various adhesions and secreted toxins, proteases, effector proteins and pigments that facilitate adhesion, modulate or disrupt host cell pathways, and target the extracellular matrix. Figure has been recreated from Hauser and Ozer (2011). Abbreviations: ADP, adenosine diphosphate; Asialo-GM1, asialo-gangliotetraocyl ceramide 1; EF2, elongation factor 2; FpvA, feeric pyoverdine receptor; PA, phosphatidic acid; RAS, ribosyltransferase; SOD1, superoxide dismutase 1; 14-3-3, 14-3-3 protein family.

### 3.2 Flagellum

The single unsheathed polar flagellum of *P. aeruginosa* is responsible for the swimming motility of this organism (Kohler, Curty, Barja, van Delden, & Pechere, 2000). Nonetheless, its role in virulence goes beyond simple motility. Flagellar proteins have been shown to play critical roles in attachment, invasion, biofilm formation and the mediation of inflammatory responses. Flagellar protein synthesis, assembly and regulation
involves more than 40 genes and is intricately controlled through transcriptional and post-translational events by the four primary regulators RpoN, FleQ, FleR and FliA (Dasgupta et al., 2003).

Non-flagellated mutants are often isolated from chronic infections in CF patients (Mahenthiralingam, Campbell, & Speert, 1994) due to the repressor activity of AlgT, which acts on the FleQ regulator (Tart, Wolfgang, & Wozniak, 2005). The loss of flagella in these isolates is believed to be useful for the invasion of the host immune system. Flagellin mediators the inflammatory response via the innate immune system, through its specific interaction with a number of pattern recognition receptors (PRRs) of the host (Verma, Arora, Kuravi, & Ramphal, 2005). Flagellin is recognized by both TLR5 (Hayashi et al., 2001) and NLRC4 (Franchi et al., 2007; Cohen, & Prince, 2013); as well NLRP3 (Kim & Jo, 2013). However, different amino acid residues of flagellin were critical for sensing by NLRC4 and TLR5 (Franchi et al., 2007). Moreover, cytosolic delivery of P. aeruginosa flagellin is required for the activation of NLRC4 (Miao, Ernst, Dors, Mao, & Aderem, 2008). Surprisingly, the NLRC4 inflammasome can be activated independently of flagellin. The flagellin-deficient strains of P. aeruginosa can efficiently activate caspase-1 in an NLRC4-dependent manner. This discrepancy as to the requirement for flagellin in NLRC4 inflammasome activation was recently explained in an elegant study by Maio and colleagues (Miao et al., 2010). They found the NLRC4 inflammasome was activated in response to the basal body rod component of the T3SS apparatus from P. aeruginosa (Pscl), as well as, other microorganisms; such as S. typhimurium (PrgJ), Burkholderia pseudomallei (BsaK), Escherichia coli (Ept1 and Escl), S. flexneri (MxiL) (Miao et al., 2010). These rod proteins contain a sequence motif that resembles one found in flagellin; hence, NLRC4 is activated by both of these similar stimuli. Furthermore, flagellar vaccines have been investigated in pre-clinical studies in mouse models and have reached phase III clinical trials for CF patients; however, limited protection was observed with a monovalent vaccine and development of a bivalent vaccine has been terminated (Doring & Pier, 2008).

3.3 Type IV Pili

The type IV pili of P. aeruginosa have a role in adhesion to many cell types and this is likely important in such phenomena as tissue tropism (attachment to particular tissues), initiation of biofilm formation and non-opsonic phagocytosis, which is mediated by phagocyte receptors that recognize corresponding adhesions on microbial surfaces (Barken et al., 2008; Mahenthiralingam & Speert, 1995; Punsalang & Sawyer, 1973). Several studies have indicated a direct correlation between the presence of glycosphingolipid on host cells and P. aeruginosa adherence, thus demonstrating the role of this glycosphingolipid as a bacterial receptor. In particular, P. aeruginosa pili bind to glycosphingolipid contained within host epithelial cell membranes; ganglio-N-tetraosylceramide (asialo-GM1) (Cornolli, Waite, Mostov, & Engel, 1999). The interaction of pili and asialo-GM1 is mediated the internalization of P. aeruginosa in host epithelial cells. In addition, these pili also mediate twitching motility, a factor found to be important in the formation of biofilms in vitro (Klausen et. al., 2003); as well as, in the initiation of dissemination from an initial point of colonization (Hahn, 1997, Klausen et. al., 2003). Although more than 50 genes have been identified to play either a direct or indirect role in the synthesis, functioning and control of the type IV pili of P. aeruginosa, the pili are composed of a single type IV pilin protein encoded by pilA (Hansen & Forest, 2006). Five alleles of pilA have been identified with group I pili being the most prevalent in CF and environmental isolates (Kus, Tullis, Cvitkovitch, & Burrows, 2004). P. aeruginosa pilin, the major component of the type IV bacterial pilus, is identified as an inflammasome-activator factor (Cecilia, Arlehamn, & Evans, 2011); as purified pilin activated caspase-1 and led to secretion of mature IL-1β.

3.4 Type III secretion System

P. aeruginosa has a variety of secretion systems of which at least four likely play a role in virulence (Type I, II, III, and IV). One of the most intriguing is T3SS that involves a flagellum-basal-body related system for delivering proteins directly from the cytoplasm of P. aeruginosa into the cytosol of host cells. A functional T3SS contributes to the successful evasion of phagocytosis by P. aeruginosa as well as damage to host tissues, promotion of immune avoidance and bacterial dissemination. The T3SS of P. aeruginosa delivers up to four cytotoxins ExoS, ExoT, ExoU and ExoY, directly to host cells (Frank, 1997; Goranson, Hovey, & Frank, 1997; Yahr, Mende-Mueller, Friese, & Frank, 1997).

ExoS and ExoT are bifunctional cytotoxins that possess both Rho GTPase-activating protein and ADP ribosyltransferase activities. These molecules can inhibit phagocytosis by disrupting actin cytoskeletal rearrangement, focal adhesions and signal transduction (Barbieri & Sun, 2004). Moreover, ExoU is a phospholipase that contributes directly to acute cytotoxicity towards epithelial cells and macrophages; while ExoY is an adenylate cyclase that affects intracellular cAMP levels and cytoskeleton reorganization (Sato & Frank, 2004; Yahr, Vallis, Hancock, Barbieri, &Frank, 1998). Recent evidence has implicated a role for the
T3SS in virulence in humans. The presence of large amount of T3SS products, particularly ExoU, in *P. aeruginosa* cultures from intubated patients was linked to increased mortality regardless of whether these patients had symptoms or confirmation of VAP (Zhuo et al., 2008). Also, *P. aeruginosa* T3SS activates NLR inflammasome. However, in the absence of any of the known effector proteins, *P. aeruginosa* T3SS apparatus is sufficient to trigger the activation of caspase-1 by the inflammasome via NLRC4 (Hauser, 2009). In another words, a functional T3SS is critical for the induction of caspase-1 activity, IL-1β secretion and cell death, whereas the effectors ExoS, ExoT and ExoY are dispensable (Franchi et al., 2007).

3.5 Exotoxin A

There are several critical virulence factors that are secret through Type II secretion mechanism, which use a pilus-like apparatus to secrete proteins into the extracellular environment, including exotoxin A, lipase, phospholipase, alkaline phosphatase, and protease; animal experiments have indicated the significant role of these factors in model infection (Passador & Iglewski, 1994). For example, exotoxin A has been demonstrated to be involved in local tissue damage and invasion. This cytotoxin is encoded by the gene toxA and has been found to be present in most clinical isolates of *P. aeruginosa*, although its role in virulence is poorly understood (Passador & Iglewski, 1994). Besides, exotoxin A enters host cells by receptor-mediated endocytosis and catalyzes the ADP-ribosylation of eukaryotic elongation factor-2 (EF-2) (Iglewski, Liu, & Kabat, 1977). EF-2 inhibits protein synthesis, which ultimately leading to cellular death.

3.6 Proteases

*P. aeruginosa* produces several secreted proteases including the zinc metalloprotease (elastase) LasB, the metalloendopeptidase LasA, and alkaline protease. These proteases work in a concerted fashion to destroy host tissue; thus, play a significant role in both acute lung infections and in burn wound infections (Bielecki, Glik, Kawecki, & Martins dos Santos, 2008; Galloway, 1991; Rumbaugh, Griswold, & Hamood, 2000). A definite role of these destructive proteases in acute infections has been established. LasA and LasB elastases have also been found in the sputum of CF patients suffering from pulmonary exacerbations of infection (Hollsing, Granstrom, Vasil, Wretlind, & Strandvik, 1987; Jagger et al., 1982); yet, their role in chronic infection is not well understood.

3.7 Alginate

*P. aeruginosa* can produce a mucoid exopolysaccharide capsule, comprised of alginate, an acetylated random co-polymer of β 1-4 linked D-mannuronic acid (poly-M) and L-guluronic acid (Gacesa & Wusteman, 1990). The overproduction of alginate is believed to play a role in cell adherence within the CF lung and is also thought to be involved in host defense by reducing susceptibility to phagocytosis (Pier, Coleman, Grout, Franklin, & Ohman, 2001), also in resistance to antibiotics. The small minorities of CF patients, who are carrying only nonmucoid *P. aeruginosa*, have significantly better lung function over time compared to those patients infected with mucoid *P. aeruginosa* (Parad, Gerard, Zurakowski, Nichols, & Pier, 1999). The tendency of *P. aeruginosa* to change to a mucoid phenotype is one of the most striking and clinically relevant features of infection by this bacterium. Additionally, poly-M shares with LPS the ability to stimulate human monocytes to cytokines production; in a CD-14-dependent manner (Otterlei et al., 1993). Involvement of TLR2 and TLR4 in cell activation by poly-M has been studied in primary murine macrophages (Flo et al., 2002).

3.8 Quorum Sensing

Quorum sensing is a mechanism of bacterial “cell-to-cell” communication via diffusible chemical compounds. A critical number of bacteria (the quorum) are required to produce a sufficient amount of a secreted signal molecule (termed an autoinducer) to trigger expression of a large regulon (Diggle, Cornelis, Williams, & Camara, 2006; Heurlier et al., 2004; Smith, Harris, Phipps, & Iglewski, 2002). Quorum sensing and biofilm development are two social phenomena exhibited by bacteria. The connection between quorum sensing and biofilms has been named sociomicrobiology (Bjarnsholt et al., 2005; Parsek & Greenberg, 2005). In addition, *P. aeruginosa* is regarded as a "model organism" in the quorum sensing field, which studied in the most detail. Quorum sensing is known to control a number of bacterial genes. More than 300 genes are regulated during quorum sensing in *P. aeruginosa* (Schuster et al., 2003).

The most common class of autoinducer used by Gram-negative bacteria is acyl-homoserine lactones (AHL), which diffuse freely across bacterial membranes. AHL signals produced by *P. aeruginosa* are oxohexanoyl-homoserine lactone and butanoyl-homoserine lactone (Pearson et al., 1994; Pearson et al., 1995). AHL signals produce by AHL synthase (LasI/RhlI), which diffuse into the environment. Increasing in bacterial density during infection leads to an increase in autoinducer concentration. When autoinducer reaches a particular
threshold, it subsequently binds to transcriptional activator (LasR/RhlR) forming a complex that activates genes involved in biofilm formation and coding virulence factors (Kipnis, Sawa, & Wiener-Kronish, 2006; Davies et al., 1998; Hirakawa & Tomita, 2013). The production of virulence factors, such as extracellular enzymes and cellular lysins (e.g. rhamnolipid) are important for the pathogenesis of infections as a protective shield against phagocytes (Jensen et al., 2007; Van Gennip et al., 2009; Alhede et al., 2009). Quorum sensing has been shown to determine the tolerance of P. aeruginosa biofilms to antibiotic therapy (Bjarnsholt et al., 2005).

Recent advances in the understanding of quorum sensing in P. aeruginosa have generated interest in using quorum sensing as a target for therapeutics. The macrolide antibiotic, azithromycin, has been a promising candidate in this regard as it has been demonstrated to be capable of both penetrating biofilms and interfering with quorum sensing (Hoffmann et al., 2007).

### 3.9 Biofilm Formation

P. aeruginosa is capable of forming complex structures called biofilms. Resistance to antimicrobial agents is the most important features of biofilm infections. Biofilm development is a complex process and partly controlled by quorum sensing signals (Figure 2). Furthermore, a variety of components play a role in the initial attachment...
of cells to the surface and development of biofilm matrix including extracellular DNA (eDNA)(Whitchurch, Tolker-Nielsen, Ragas, and Mattick. 2002), exopolysaccharide (Psl, Pel, and alginate) (Ma et al., 2009; Karatan & Watnick, 2009), iron siderophore pyoverdine, biosurfactant rhamnolipid (Harmsen, Yang, Pamp, Tolker-Nielsen, 2010), and proteinaceous surface appendages such as type IV pili, flagella (Klausen, Aaes-Jorgensen, Molin, & Tolker-Nielsen, 2003), Cup fimbria (Vallet et al., 2001). Nevertheless, there are still numerous factors that are involved in biofilm formation process and dispersion, which are related to signals, regulatory networks, and materials, reviewed elsewhere (Harmsen, Yang, Pamp, Tolker-Nielsen, 2010; Wei & Ma, 2013; Karatan & Watnick, 2009).

During biofilm formation, cell differentiation occurs, and oxygen and water-filled channels are formed to provide nutrition to the deep-rooted cells of the mature biofilm (Davies, 2002; Friedman and Kolter, 2004; Kirisits, Prost, Starkey, & Parsek, 2005; Ryder, Byrd, & Wozniak, 2007). *P. aeruginosa* has been demonstrated to form biofilms on a variety of indwelling medical devices (Choong & Whitfield, 2000; Khoury, Lam, Ellis, & Costerton, 1992). It is particularly problematic for patients requiring mechanical ventilation and catheterization, as the surfaces of medical devices can readily develop *P. aeruginosa* biofilms that are difficult to remove. Also, *P. aeruginosa* has been demonstrated to grow as a biofilm within the body particularly at the site of burn wounds. It has been proposed that *P. aeruginosa* exists as a biofilm in the CF lung (Consterton, Stewart, & Greenberg, 1999; Singh et al., 2000) and this has been observed in a mouse model of CF lung infection (Hoffmann et al., 2005).

In addition to evasion of the host immune system, the highly antibiotic resistant nature of biofilms to killing by bactericidal antibiotics contributes to bacterial persistence in chronic infections (Mah, Pitts, Pellock, Walker, Stewart, & O'Toole, 2003). It has been demonstrated that cells growing in a biofilm can be up to 1000 fold more resistant to antibiotics than free-swimming, planktonic cells (Hoyle & Costerton, 1991). Biofilms present not only a diffusion barrier to antibiotics, but also the cells in a biofilm have been demonstrated to have significantly different expression patterns compared to their planktonic counterparts (Sauer, Camper, Ehrlich, Costerton, & Davies, 2002).

### 3.10 Type VI Secretion Systems

Bacterial pathogens frequently possess number of secretion systems that function to translocate protein secretion. The T6SS represents one of the most recently recognized examples of these secretion systems. An interest in bacterial pathogens frequently possess number of secretion systems that function to translocate protein secretion.
reason, induction of both PldB and H3-T6SS in these conditions may allow better colonization of the lung epithelium through invasion. These findings reveal a function for the \textit{P. aeruginosa} H3-T6SS effector PldB and show that PldB and PldA can influence both bacterial competition and interaction with mammalian hosts. T6SSs are promising targets for the development of new approaches to diagnosis, vaccine development and antimicrobial drug design (Yahr, 2006; Baron & Coombes, 2007).

3.11. Oxidant Generation in the Airspace

Oxidative stress refers to an imbalance in the redox status of the cell favoring an oxidizing environment. Extensive reactive oxygen species (ROS) production leads to the depletion of antioxidants and results in cellular damage. In particular, ROS can damage DNA strands by reacting with base pairs and the deoxyribose phosphate backbone of DNA, the primary target of radical damage (Gram, 1997). Without the protection of antioxidants, ROS can also initiate lipid peroxidation of polyunsaturated fatty acid components of cell membrane phospholipids, affecting cellular integrity (Rahman & Adcock, 2006). Amino acids can also be damaged by ROS, leading to protein denaturation and enzyme deactivation (Gram, 1997; Rahman & Adcock, 2006). When left unmanaged, oxidative stress can eventually lead to cell death.

During the infectious process, \textit{P. aeruginosa} induces ROS production within epithelial cells in a few ways. Following its secretion into the microenvironment, pyocyanin permeates the epithelial cell membrane and directly oxidizes intracellular pools of NADPH and glutathione, producing superoxide and downstream ROS (Rada, Gardina, Myers, & Leto, 2011). Recognition of \textit{P. aeruginosa} LPS by the epithelial cells leads to ROS production through protein kinase C (PKC)-NADPH oxidase signaling pathway in human epithelial cells (Yan, Li, Jono, Li, Zhang, Li, & Shen, 2008). Other potential sources of ROS are derived from the activated epithelium via induction of the mitochondrial electron transport chain, cytochrome p450, and xanthine oxidase. In the case of mechanical ventilation, the introduction of excess oxygen can also fuel the production of ROS (Chow, Herrera, Suzuki, & Downey, 2003). In acute lung injury, however, stimulated phagocytes produce the majority of ROS (Ward, 2010). Overwhelming oxidant injury may lead to alveolar collapse and extensive fibrotic scarring, impairing gas exchange between the affected airways and the capillary system (Ward, 2010).

4. Antimicrobial Resistance

\textit{P. aeruginosa} can be an especially challenging organism to treat once infection has been established as it is intrinsically resistant to many of the available antibiotics. Three mechanisms have been studied by which \textit{P. aeruginosa} resist the action of antibiotics. The outer membrane of \textit{P. aeruginosa} is restricted the penetration of antibiotics and the efficient removal of antibiotics molecules by efflux pumps before acting on their targets. \textit{P. aeruginosa} has the genetic capacity to inactivate and modify of antibiotics. This bacterium can become resistant through mutational changes in antibiotic’s targets (Lambert, 2002). Consequently, \textit{P. aeruginosa} has now achieved the status superbug. This section will provide an overview of the main mechanisms of resistance present in clinical isolates of \textit{P. aeruginosa}.

4.1 Intrinsic Resistance

\textit{P. aeruginosa} exhibits intrinsic resistance to almost all of the available antibiotics, indicating that the wild-type strain possesses number of genetic mechanisms that contribute to reducing susceptibility of the organisms. One of the major factors contributing to this intrinsic resistance is the low permeability of its outer membrane. The outer membrane is essential for passively determining the rate of uptake of antibiotics and small molecules (Hancock, 1998). However, by itself this is insufficient to mediate significant resistance, and antibiotics will equilibrate across the outer membrane. Thus, intrinsic resistance arises from the combination of slow uptake and secondary mechanisms that benefit from this slow uptake including degradative enzymes such as periplasmic \(\beta\)-lactamase and particularly multidrug efflux systems. There are at least four antibiotic efflux systems have been described including MexAB-OprM and MexXY-OprM, MexCD-OprM, and MexEF-oprN elsewhere (Hancock, 1998; Poole, 2001; Lambert, 2002; Lister, Wolter, & Hanson, 2009).

The \textit{P. aeruginosa} outer membrane is an asymmetric membrane composed of an inner leaflet of phospholipid, predominantly phosphatidylethanolamine, an outer layer of polyanionic LPS. The latter presents a negatively charged surface, which, together with the divalent cations bridging the individual LPS molecules, forms a matrix around the cell that is relatively impermeable to polar compounds except polycations (Hancock, 1997). Multidrug efflux pumps also mediated resistance to many classes of antibiotics. The \textit{P. aeruginosa} genome contains a large number of drug efflux systems (Stover et al., 2000), which have been categorized into five superfamilies include: the small multidrug resistance family, the ATP-binding cassette family, the multidrug and toxic compound extrusion family, the resistance-nodulation-cell division family, and major facilitator...

*P. aeruginosa* also expresses periplasmic β-lactamases to degrade β-lactam antibiotics. β-lactamases are hydrolyzing enzymes that cleave the lactam ring of penicillins, carbapenems, cephalosporins and monobactams, thus leading to inactivation of the antibiotic (Richmond and Sykes, 1973; Sanders, 1992; Sykes and Matthew, 1976). In *P. aeruginosa*, this activity is due to a chromosomally encoded AmpC β-lactamase. The AmpC β-lactamase of *P. aeruginosa* can degrade and contribute to intrinsic resistance to ticarcillin, piperacillin and the third-generation cephalosporins. It is strongly induced by carbapenems, particularly imipenem, although these inducing carbapenems are stable against its hydrolytic activity (Balasubramanian et al., 2012).  

4.2 Adaptive Resistance

Discrepancies between in *in vitro* susceptibility of *P. aeruginosa* isolates and treatment outcomes in CF patients have been observed, and, can be attributed to the phenomenon of adaptive resistance. Adaptive resistance occurs when cell populations are exposed to non-lethal concentrations of antibiotic and undergo specific changes in gene expression that result in reduced susceptibility. It is a form of inducible resistance that does not require the presence of mutations; it has been demonstrated in *in vitro* using CF isolates and in mouse models, when isolates were pre-incubated with subinhibitory concentrations of antibiotics (Barclay, Begg, Chambers, Thorley, Pattemore, & Grimwood, 1996; Brazas and Hancock, 2005; Gilleland, Gilleland, Gibson, & Champlin, 1989). However, the concern arises that this induction may allow small population to survive and acquire stably resistant mutations. Similarly, polymyxin susceptibility in *P. aeruginosa* is associated with the LPS structure, which is determined by *arnBCADTFE* and modulated by PhoPQ and PmrAB (Barrow and Kwon, 2009). Adaptive resistance to polymyxins and antimicrobial peptides has been shown to occur through altered expression of the PhoPQ and PmrAB systems in response to these agents. This also leads to modulation of Lipid A fatty acid composition (Moskowitz, Ernst, & Miller, 2004), which ultimately affects resistance to not only polymyxin and antimicrobial peptides, but also the aminoglycosides, which rely on the LPS binding for self-promoted uptake.

4.3 *P. aeruginosa* as a Superbug

The accumulation of multiple resistance mechanisms in clinical isolates of *P. aeruginosa* has resulted in strains that are resistance to all available antibiotics. This pandrug resistance, which means resistant to all antimicrobial agents, together with high attributable mortality, has thrust *P. aeruginosa* into the spotlight as an emerging superbug. According to report by the National Nosocomial Infections Surveillance (NNIS) System, which focused on nosocomial infections in ICU, not only were resistance rates increasing, but the incidence of occurrence of most infection types was also increasing (Gaynes and Edwards, 2005). In 2003, the NNIS reported a 9% increase in resistance to the third generation cephalosporins, a 15% increase in ciprofloxacin resistance, and most alarming, a 47% increase in imipenem resistance over a five year period. According to the European Antimicrobial Resistance Surveillance System 18% of *P. aeruginosa* isolates were multidrug resistance with 6% of all isolates being resistant to piperacillin, ceftazidime, fluoroquinolones, aminoglycosides and carbapenems (Souli, Galani, & Giamarellou, 2008). The drug of last resort for infections with multidrug resistance *P. aeruginosa* is colistin (polymyxin E), and while resistance rates remain low (approximately 1% in most countries), mortality of 80% has been observed for infections caused by colistin resistant Gram-negative bacilli (Beno, Krcmery, & Demitrovicova, 2006).

5. Conclusion

In conclusion, it would be impossible to remove *P. aeruginosa* from the environment, even the internal environment of the hospital because it is so hardy and metabolically versatile. However, the last two decades have seen a remarkable addition to active medication and therapy to the regimen for treating CF lung infection. These therapies have enhanced the overall health of patients with CF and, they are apparently part of the reason that demanded survival has increased. However, these therapies do not offer a cure and they primarily treat downstream complications of the pathophysiology of CF lung infection, meaning that patients persist to undergo the morbidity associated with chronic airway infection; predicted survival still lags well below what is normal. However, innate immunity is critical in protecting the host from bacterial invasion, but at the same time it can directly & indirectly damage tissues. In addition, these therapies add to a considerable treatment burden and are thus also associated with poor adherence. What is more, it appears likely that the antibiotic resistance will continue to be a problem in dealing with *P. aeruginosa* infections. The fundamental issues underlying this problem are the condition of the patients that are prone to such infections, and, the high intrinsic resistance of
this bacterium, which have remained constant. Chronic *P. aeruginosa* airway infection and the accompanying inflammatory response are clearly the significant clinical problems for CF patients today. Instead, we need an urgent alternative therapeutic strategy.

**Acknowledgment**

This work was supported by scholarship award granted to A. Alhazmi, from Jazan University, through Saudi Arabian Cultural Bureau in Canada.

**References**


Copyrights

Copyright for this article is retained by the author(s), with first publication rights granted to the journal.

This is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).